Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of$ 0.83. This compares to loss of $0.90 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 1.20%. A quarter ago, it was expected that this company would post a loss of$ 0.69 per share when it actually produced a loss of $0.58, delivering a surprise of 15.94%. Over the last four quarters, the company h ...